Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy

Invasive meningococcal disease is a global public-health concern, with infants and adolescents bearing the majority of the disease burden. Vaccination is the most rational strategy to prevent meningococcal disease. Control of serogroup C disease has largely been achieved by the introduction of glycoconjugate meningococcal C vaccines, initially in the UK in 1999, and subsequently in several other countries. The recent licensure of a quadrivalent glycoconjugate vaccine against serogroups A, C, Y and W-135 in the USA and Canada has broadened protection against Neisseria meningitidis in 2–55 year olds. The investigational quadrivalent meningococcal serogroup A, C, Y and W-135 glycoconjugate vaccine (MenACYW–CRM197), which is immunogenic from infancy, has the potential to extend protection to the most vulnerable age group. This article discusses this novel quadrivalent vaccine formulation and its potential to control invasive disease caused by N. meningitidis serogroups A, C, Y and W-135.

[1]  R. Schneerson,et al.  Polysaccharide–Protein Conjugate Vaccines , 2011 .

[2]  P. Dull,et al.  Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. , 2010, Vaccine.

[3]  J. Langley,et al.  Immunogenicity and Immune Memory of a Nonadjuvanted Quadrivalent Meningococcal Glycoconjugate Vaccine in Infants , 2009, The Pediatric infectious disease journal.

[4]  K. Reisinger,et al.  A Randomized Trial to Determine the Tolerability and Immunogenicity of a Quadrivalent Meningococcal Glycoconjugate Vaccine in Healthy Adolescents , 2009, The Pediatric infectious disease journal.

[5]  C. Frasch,et al.  Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa. , 2009, Vaccine.

[6]  J. Poolman,et al.  Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. , 2009, Vaccine.

[7]  A. Wilder-Smith.  Meningococcal disease: risk for international travellers and vaccine strategies. , 2008, Travel medicine and infectious disease.

[8]  D. Kelly,et al.  Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study , 2008, BMJ : British Medical Journal.

[9]  Q. Jin,et al.  Genetic characteristics of serogroup A meningococci circulating in China, 1956-2005. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[10]  R. Rappuoli,et al.  Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases. , 2008, Vaccine.

[11]  M. Maiden,et al.  Molecular epidemiology of meningococcal disease in England and Wales 1975–1995, before the introduction of serogroup C conjugate vaccines , 2008, Microbiology.

[12]  S. Schrag,et al.  Emergence of endemic serogroup W135 meningococcal disease associated with a high mortality rate in South Africa. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  J. Langley,et al.  Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. , 2008, JAMA.

[14]  J. Mond,et al.  The multifunctional role of antibodies in the protective response to bacterial T cell-independent antigens. , 2008, Current topics in microbiology and immunology.

[15]  Report from the Advisory Committee on Immunization Practices (ACIP): decision not to recommend routine vaccination of all children aged 2-10 years with quadrivalent meningococcal conjugate vaccine (MCV4). , 2008, MMWR. Morbidity and mortality weekly report.

[16]  B. Greenwood,et al.  Systematic review: Impact of meningococcal vaccination on pharyngeal carriage of meningococci , 2007, Tropical medicine & international health : TM & IH.

[17]  B. Greenwood,et al.  Meningococcal carriage in the African meningitis belt. , 2007, The Lancet. Infectious diseases.

[18]  N. Klein.  Safety and Immunogenicity 12 months Post-Vaccination with Novartis Vaccines' Tetravalent Glycoconjugate Meningococcal ACWY Vaccine in Children Aged 2-10 Years , 2007 .

[19]  A. Pollard,et al.  Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines , 2007, Archives of Disease in Childhood.

[20]  R. Borrow,et al.  Issues surrounding standardization of meningococcal group W135 serology. , 2007, Vaccine.

[21]  M. Préziosi,et al.  The Meningitis Vaccine Project. , 2007, Vaccine.

[22]  A. Pollard,et al.  Reconsideration of the Use of Meningococcal Polysaccharide Vaccine , 2007, The Pediatric infectious disease journal.

[23]  D. Caugant,et al.  Serogroup X in Meningococcal Disease, Western Kenya , 2007, Emerging infectious diseases.

[24]  D. Caugant,et al.  Meningitis Serogroup W135 Outbreak, Burkina Faso, 2002 , 2007, Emerging infectious diseases.

[25]  O. Bilukha,et al.  Use of Meningococcal Vaccines in the United States , 2007, The Pediatric infectious disease journal.

[26]  S. Chanteau,et al.  Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  R. Booy,et al.  Impact of meningococcal C conjugate vaccine use in Australia , 2007, The Medical journal of Australia.

[28]  K. Jolley,et al.  A surveillance network for meningococcal disease in Europe. , 2007, FEMS microbiology reviews.

[29]  N. Andrews,et al.  Social Behavior and Meningococcal Carriage in British Teenagers , 2006, Emerging infectious diseases.

[30]  H. D. de Melker,et al.  PROTECTION FROM ROUTINE VACCINATION AT THE AGE OF 14 MONTHS WITH MENINGOCOCCAL SEROGROUP C CONJUGATE VACCINE IN THE NETHERLANDS , 2006, The Pediatric infectious disease journal.

[31]  Antonio E Pérez,et al.  "Bacterial Meningitis in children and adolescents: an observational study based on the national surveillance system" , 2005, BMC infectious diseases.

[32]  H. Keyserling,et al.  Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. , 2005, Archives of pediatrics & adolescent medicine.

[33]  N. Andrews,et al.  Serologic Responses to ACYW135 Polysaccharide Meningococcal Vaccine in Saudi Children under 5 Years of Age , 2005, Infection and Immunity.

[34]  Daniel J. Wilson,et al.  Genetic analysis of meningococci carried by children and young adults. , 2005, The Journal of infectious diseases.

[35]  E. Miller,et al.  Meningococcal surrogates of protection--serum bactericidal antibody activity. , 2005, Vaccine.

[36]  R. Rappuoli,et al.  The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease. , 2005, Vaccine.

[37]  A. van Belkum,et al.  Epidemiology of nasopharyngeal carriage of Neisseria meningitidis in healthy Dutch children. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  D. Caugant,et al.  Characterization ofNeisseria meningitidis serogroup A strains from an outbreak in France by serotype, serosubtype, multilocus enzyme genotype and outer membrane protein pattern , 1991, European Journal of Clinical Microbiology and Infectious Diseases.

[39]  N. Andrews,et al.  Serologic Responses to ACYW 135 Polysaccharide Meningococcal Vaccine in Saudi Children under 5 Years of Age , 2005 .

[40]  A. Pollard.  Global Epidemiology of Meningococcal Disease and Vaccine Efficacy , 2004, The Pediatric infectious disease journal.

[41]  D. Lennon,et al.  The Strategy to Control New Zealand's Epidemic of Group B Meningococcal Disease , 2004, The Pediatric infectious disease journal.

[42]  Daniel J. Wilson,et al.  Distribution of Serogroups and Genotypes among Disease-Associated and Carried Isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway , 2004, Journal of Clinical Microbiology.

[43]  A. Schuchat,et al.  Immunogenicity, safety, and memory of different schedules of Neisseria meningitidis A/C-diphtheria toxoid conjugate vaccine in infants in Niger. , 2004, Vaccine.

[44]  Elizabeth Miller,et al.  Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction , 2004, The Lancet.

[45]  M. Rennels,et al.  Dosage Escalation, Safety and Immunogenicity Study of Four Dosages of a Tetravalent Meninogococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Infants , 2004, The Pediatric infectious disease journal.

[46]  M. Bakır,et al.  Asymtomatic carriage of Neisseria meningitidis and Neisseria lactamica in relation to Streptococcus pneumoniae and Haemophilus influenzae colonization in healthy children: Apropos of 1400 children sampled , 2004, European Journal of Epidemiology.

[47]  M. Taha,et al.  Neisseria meningitidis strains isolated from invasive infections in France (1999-2002): phenotypes and antibiotic susceptibility patterns. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  N. Andrews,et al.  Validation of Serological Correlate of Protection for Meningococcal C Conjugate Vaccine by Using Efficacy Estimates from Postlicensure Surveillance in England , 2003, Clinical Diagnostic Laboratory Immunology.

[49]  Á. Domínguez,et al.  Dramatic decline of serogroup C meningococcal disease in Catalonia (Spain) after a mass vaccination campaign with meningococcal C conjugated vaccine. , 2003, Vaccine.

[50]  A. Wilder-Smith,et al.  Acquisition of W135 meningococcal carriage in Hajj pilgrims and transmission to household contacts: prospective study , 2002, BMJ : British Medical Journal.

[51]  M. Maiden,et al.  Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination , 2002, The Lancet.

[52]  Andrew P. Morse,et al.  Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa. , 2002, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[53]  M. Ramsay,et al.  Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. , 2001, Vaccine.

[54]  J. Capparella,et al.  Risk factors for meningococcal disease in college students. , 2001, JAMA.

[55]  L. Calder,et al.  Carriage of Neisseria meningitidis Among Household Contacts of Patients with Meningococcal Disease in New Zealand , 2001, European Journal of Clinical Microbiology and Infectious Diseases.

[56]  S. Tyski,et al.  Phenotypical and Genotypical Characterization of Neisseria meningitidis Carrier Strains Isolated from Polish Recruits in 1998 , 2001, European Journal of Clinical Microbiology and Infectious Diseases.

[57]  M. Achtman,et al.  Molecular epidemiology of serogroup a meningitis in Moscow, 1969 to 1997. , 2001, Emerging infectious diseases.

[58]  T. Popović,et al.  Meningococcal disease. , 2001, The New England journal of medicine.

[59]  Oleg O. Bilukha,et al.  Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2000, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[60]  M. Achtman,et al.  Serogroup W135 meningococcal disease in Hajj pilgrims , 2000, The Lancet.

[61]  J. Deeks,et al.  Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. , 2000, JAMA.

[62]  J. Nguyen-Van-Tam,et al.  Dynamics of Meningococcal Long-Term Carriage among University Students and Their Implications for Mass Vaccination , 2000, Journal of Clinical Microbiology.

[63]  J. Nguyen-Van-Tam,et al.  Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study , 2000, BMJ : British Medical Journal.

[64]  J. Deeks,et al.  Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. , 1999, Vaccine.

[65]  R. Gupta,et al.  Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. , 1998, The Journal of infectious diseases.

[66]  M. Rennels,et al.  Safety and Immunogenicity of Heptavalent Pneumococcal Vaccine Conjugated to CRM197 in United States Infants , 1998, Pediatrics.

[67]  J. Taylor,et al.  Efficacy of meningococcal vaccine and barriers to vaccination. , 1998, JAMA.

[68]  R. Harpaz,et al.  Prevention of plague: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 1996, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[69]  C. Snapper,et al.  T cell-independent antigens type 2. , 1995, Annual review of immunology.

[70]  E. Ford,et al.  Surveillance for diabetes mellitus--United States, 1980-1989; and Laboratory-based surveillance for meningococcal disease in selected areas--United States, 1989-1991 , 1993 .

[71]  J. Hanna,et al.  Epidemic meningococcal meningitis in central Australia, 1987–1991 , 1993, The Medical journal of Australia.

[72]  P. Moore,et al.  Respiratory viruses and mycoplasma as cofactors for epidemic group A meningococcal meningitis. , 1990, JAMA.

[73]  J. Stuart,et al.  Risk factors for meningococcal disease: a case control study in south west England. , 1988, Community medicine.

[74]  K. Cartwright,et al.  The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica , 1987, Epidemiology and Infection.

[75]  M. Lepow,et al.  Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children. , 1986, The Journal of infectious diseases.

[76]  C. Adamsbaum,et al.  AGE-SPECIFIC DIFFERENCES IN DURATION OF CLINICAL PROTECTION AFTER VACCINATION WITH MENINGOCOCCAL POLYSACCHARIDE A VACCINE , 1985, The Lancet.

[77]  A. Safary,et al.  Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides. , 1985, Pediatrics.

[78]  R. Mandrell,et al.  Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide , 1983, Infection and immunity.

[79]  B. Greenwood,et al.  The epidemiology of infections due to Neisseria meningitidis and Neisseria lactamica in a northern Nigerian community. , 1982, The Journal of infectious diseases.

[80]  H. Peltola,et al.  Meningococcal disease in Scandinavia. , 1982, British medical journal.

[81]  J. Armand,et al.  Tetravalent meningococcal polysaccharide vaccine groups A, C, Y, W 135: clinical and serological evaluation. , 1982, Journal of biological standardization.

[82]  I. Goldschneider,et al.  Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. , 1978, The Journal of infectious diseases.

[83]  E. Gotschlich,et al.  Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. , 1975, The Journal of clinical investigation.

[84]  E. Gotschlich,et al.  A controlled field trial of a serogroup A meningococcal polysaccharide vaccine. , 1973, Bulletin of the World Health Organization.

[85]  M. Artenstein,et al.  Prevention of meningococcal disease by group C polysaccharide vaccine. , 1970, The New England journal of medicine.

[86]  M. Artenstein,et al.  HUMAN IMMUNITY TO THE MENINGOCOCCUS IV. IMMUNOGENICITY OF GROUP A AND GROUP C MENINGOCOCCAL POLYSACCHARIDES IN HUMAN VOLUNTEERS , 1969 .

[87]  M. Artenstein,et al.  Human immunity to the meningococcus. II. Development of natural immunity. , 1969 .

[88]  M. Artenstein,et al.  HUMAN IMMUNITY TO THE MENINGOCOCCUS I. THE ROLE OF HUMORAL ANTIBODIES , 1969 .